Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26983176 | 0.82 | CA12 (0.63) | LARS1CA2CA1CA12CA9 | |
| SCHEMBL174174 | 0.79 | KEAP1 (0.56) | KDM4ECA12CA9GAASMN1; SMN2 | |
| SCHEMBL1269819 | 0.77 | CA2 (0.54) | KDM4ELARS1CA2CA1CA12 | |
| SCHEMBL9503197 | 0.75 | CA2 (0.57) | KDM4ELARS1CA2CA1CA12 | |
| SCHEMBL21780201 | 0.75 | MALT1 (0.47) | KDM4ELARS1CA2CA1CA12 | |
| SCHEMBL451810 | 0.73 | CYP3A4 (0.69) | KDM4ECA2CA1CA12CA9 | |
| SCHEMBL1161379 | 0.73 | EGFR (0.55) | KDM4ELARS1CA2CA1HPGD | |
| Hydrochloric Acid SCHEMBL5015149 | 0.72 | CYP3A4 (0.67) | KDM4ECA2CA1CA12CA9 | |
| SCHEMBL14058721 | 0.71 | CA2 (0.47) | KDM4ELARS1CA2CA1CA12 | |
| Acetic Acid SCHEMBL27681643 | 0.71 | BCAT1 (0.51) | KDM4ELARS1CA2CA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617198-B1 | GUANIDINE DERIVATIVE | LUNAN PHARMACEUTICAL GROUP CORP (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20200325109-A1 | IMINO-UREA DERIVATIVES | Carolina Cloud Exchange Inc. | 2020-10-15 | — | — | US | disclosed |
| EP-3617198-A1 | GUANIDINE DERIVATIVE | Lunan Pharmaceutical Group Corporation (CN) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325109-A1 | IMINO-UREA DERIVATIVES | IDO2, IDO1, INMT | KDM4E 1479/4885LARS1 3762/4885CA2 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.